Nancy Elilzabeth Brightman, MS, PSYD | |
433 Canaan St, Canaan, NH 03741-7625 | |
(603) 481-2453 | |
Not Available |
Full Name | Nancy Elilzabeth Brightman |
---|---|
Gender | Female |
Speciality | Psychologist - School |
Location | 433 Canaan St, Canaan, New Hampshire |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1942927025 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TS0200X | Psychologist - School | 101962 (New Hampshire) | Primary |
Mailing Address | Practice Location Address |
---|---|
Nancy Elilzabeth Brightman, MS, PSYD 433 Canaan St, Canaan, NH 03741-7625 Ph: (603) 481-2453 | Nancy Elilzabeth Brightman, MS, PSYD 433 Canaan St, Canaan, NH 03741-7625 Ph: (603) 481-2453 |
News Archive
EvoNexus a San Diego-based incubator for technology startup companies, today announces the graduation of TruMed Systems, creators of the turnkey Vaccine Management Solution AccuVax.
Dr. Julie Gerberding, director, Centers for Disease Control and Prevention ,speaking at the National Immunization Conference Washington, DC, says the rubella virus, a major cause of serious birth defects such as deafness and blindness, also known as congenital rubella syndrome (CRS) is no longer considered to be a major public health threat in the United States.
Cannabis Medical Solutions Inc. a leading company specializing in merchant payment solutions and financial products for the medical marijuana industry, today announced that the Company was featured this week as a top stock pick for investors within the medical marijuana sector by the Denver Examiner and special news report .
Researchers of Apoptosis and Cancer Group of the Bellvitge Biomedical Research Institute (IDIBELL) have found that a small molecule, Nutlin-3a, an antagonist of MDM2 protein, stimulates the signalling pathway of another protein, p53.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technologies, announced today that the first patients have been enrolled in the INNOVATION trial, which will assess the safety of a new stent graft system, called INCRAFT™, to treat abdominal aortic aneurysm (AAA). An estimated 27 million people worldwide have abdominal aortic aneurysms.
› Verified 8 days ago